GSK’s Velzatinib Receives Japan Orphan Drug Designation For GIST, Supported By StrateGIST 1 Data; Adds To US FDA Fast Track, US, EU ODDs, Phase III Trials Under Way

Benzinga · 1d ago
  • Designation supported by StrateGIST 1 data showing promising anti-tumour activity and tolerability profile
  • Adds to US FDA Fast Track Designation and ODDs in the US and EU
  • Phase III studies accelerated in first- and second-line GIST